摘要
尽管传统癌症化疗方法已取得明显的进展,但由于化疗药物的多药耐药性及毒副作用限制其应用。为了克服多药耐药性,需要增加药物剂量及用药次数,反而导致更强的毒副作用,最终限制了化疗药物的临床使用。阳离子脂质体作为新型基因与药物传递系统,近年来备受众多研究学者的青睐。最重要的是阳离子脂质体共载基因与化疗药物进行联合治疗具有良好的协同增效作用,主要是外源基因可以沉默相关基因的表达,且提高胞内化疗药物浓度。该方法可以减少药物的使用剂量以达到相同治疗效果。从某种程度上克服了传统化疗的主要限制。因此在未来癌症治疗中,共载基因与药物联合治疗递送体系将发挥更大作用,特别有望用于多药耐药肿瘤中的临床治疗。
Despite recent advances in conventional therapeutic approaches for cancer,the efficacy of chemotherapy for cancer is limited due to the drug resistance and toxic side effects during treatment.To overcome drug resistance,higher doses of the toxic chemotherapy drugs are frequently administered,thus leading to even severe adverse side effects,which have limited their clinical application.Cationic liposome as a novel non-viral carrier for co-delivery of gene and chemotherapy drugs in cancer gene therapy has already attracted more and more attention in recent years.Most importantly,this combined strategy can generate a significant synergistic effect,which can silence the related gene expression and increase the concentration of the intracellular chemotherapy drugs.This approach allows the use of a much lower dose of the chemotherapy drugs to achieve same therapeutic effect,which may have the potential for overcoming some major limitations of the conventional chemotherapy.In conclusion,co-delivery of gene and chemotherapy drugs with cationic liposome delivery system will play a vital role in the future and especially could be a promising clinical treatment for drug-resistant tumors.
出处
《药学学报》
CAS
CSCD
北大核心
2012年第8期986-992,共7页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(31170939
81171471
51103049)
福建省自然科学基金资助项目(2010J05027
2011J01223)
关键词
阳离子脂质体
基因
化疗药物
共载
肿瘤治疗
cationic liposome； gene； chemotherapy drug； co-delivery； cancer therapy
